These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6171429)

  • 1. Expression of normal histocompatibility antigens in murine lymphomas treated with 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vivo.
    Taramelli D; Romani L; Bonmassar A; Goldin A; Fioretti MC
    Eur J Cancer (1965); 1981 Apr; 17(4):411-20. PubMed ID: 6171429
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
    Romani L; Fioretti MC; Bonmassar E
    Transplantation; 1979 Sep; 28(3):218-22. PubMed ID: 494379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo.
    Santoni A; Kinney Y; Goldin A
    J Natl Cancer Inst; 1978 Jan; 60(1):109-12. PubMed ID: 146746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
    Bonmassar A; Frati L; Fioretti MC; Romani L; Giampietri A; Goldin A
    Eur J Cancer (1965); 1979 Jul; 15(7):933-9. PubMed ID: 488153
    [No Abstract]   [Full Text] [Related]  

  • 5. [In vitro cytolysis mediated by NK effectors: modification of the susceptibility of the target cell by in vivo treatment with DTIC].
    Migliorati G; Romani L; Fioretti MC
    Boll Soc Ital Biol Sper; 1981 May; 57(9):1024-30. PubMed ID: 7284118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens.
    Romani L; Grohmann U; Fazioli F; Puccetti P; Mage MG; Fioretti MC
    Cancer Immunol Immunother; 1988; 26(1):48-54. PubMed ID: 3257903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
    Testorelli C; Franco P; Goldin A; Nicolin A
    Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional studies of H-2k-like epitopes on DTIC treated and untreated L1210 (H-2d) clones.
    Marelli OE; Franco P; Labeta MO; Festenstein H
    J Immunogenet; 1989; 16(4-5):373-80. PubMed ID: 2639909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
    Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
    Nicolin A; Franco P; Testorelli C; Goldin A
    Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma.
    Franco P; Veronese F; Levi F; Goldin A; Nicolin A
    Br J Cancer; 1982 Aug; 46(2):173-9. PubMed ID: 7150471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity.
    Fioretti MC; Bianchi R; Romani L; Bonmassar E
    J Natl Cancer Inst; 1983 Dec; 71(6):1247-51. PubMed ID: 6581361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-mediated changes of tumour cell immunogenicity and antigenicity.
    Puccetti P; Romani L; Taramelli D; Bonmassar E; Fioretti MC
    Int J Tissue React; 1982; 4(3):189-99. PubMed ID: 6183194
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunological cross-reactivity between H-2Dk product and DTIC-treated H-2d lymphoma.
    Marelli O; Testorelli C; Canti G; Festenstein H; Nicolin A
    J Immunogenet; 1982 Dec; 9(6):407-12. PubMed ID: 6186748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.
    Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A
    Transplantation; 1978 Feb; 25(2):63-8. PubMed ID: 146282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic variation in cancer metastasis: immune escape versus immune control.
    Schirrmacher V; Fogel M; Russmann E; Bosslet K; Altevogt P; Beck L
    Cancer Metastasis Rev; 1982; 1(3):241-74. PubMed ID: 6985248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo.
    Romani L; Puccetti P; Fioretti MC; Mage MG
    Int J Cancer; 1985 Aug; 36(2):225-31. PubMed ID: 3894248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L1210/DTIC antigenic subline: studies at the clone level.
    Marelli O; Canti G; Franco P; Prandoni N; Ricci L; Nicolin A
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1401-5. PubMed ID: 2435557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated immunity to Friend virus-induced leukemia.
    Ting CC; Shiu G; Rodrigues D; Herberman RB
    Cancer Res; 1974 Jul; 34(7):1684-7. PubMed ID: 4134674
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.